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A number of different viruses including respiratory syncytial virus (RSV) initiate infection of cells by bind-
ing to cell surface glycosaminoglycans and sulfated oligo- and polysaccharide mimetics of these receptors
exhibit potent antiviral activity in cultured cells. We investigated whether the introduction of different
lipophilic groups to the reducing end of sulfated oligosaccharides would modulate their anti-RSV activity.
Our results demonstrate that the cholestanol-conjugated tetrasaccharide (PG545) exhibited 5- to 16-
fold enhanced anti-RSV activity in cultured cells compared with unmodiﬁed sulfated oligosaccharides.
Furthermore, PG545 displayed virus-inactivating (virucidal) activity, a feature absent in sulfated oligo-
saccharides. To inhibit RSV infectivity PG545 had to be present during the initial steps of viral infection
of cells. The anti-RSV activity of PG545 was due to both partial inhibition of the virus attachment to cells
and a more profound interference with some post-attachment steps as PG545 efﬁciently neutralized
infectivity of the cell-adsorbed virus. The anti-RSV activity of PG545 was reduced when tested in the
presence of human nasal secretions. Serial passages of RSV in the presence of increasing concentrations
of PG545 selected for weakly resistant viral variants that comprised the F168S and the P180S amino acid
substitutions in the viral G protein. Altogether we identiﬁed a novel and potent inhibitor of RSV, which
unlike sulfated oligo- and polysaccharide compounds, could irreversibly inactivate RSV infectivity.
 2011 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
To initiate infection of susceptible cells, viruses frequently bind
to cell surface carbohydrate residues such as sialic acid or sulfated
glycosaminoglycan (GAG) chains, which represent attractive tar-
gets for antiviral intervention. In fact, speciﬁc mimetics of sialic
acid are already approved for treatment of inﬂuenza virus infec-
tions (Von Itzstein et al., 1993). In contrast, mimetics of GAG chains
such as sulfated polysaccharides or other polysulfonated com-
pounds potently inhibit infection of cultured cells by many differ-
ent GAG-binding viruses including human immunodeﬁciency virus
(HIV), herpes simplex virus (HSV), and respiratory syncytial virus
(RSV) (for reviews, see Vaheri, 1964; Witvrouw and De Clercq,+46 31 827032.
. Trybala).
epartment of Pharmaceutical
onship, Department of Chem-
mpus Universitário Trindade,
iology, University of Gothen-
ar Biosciences, The University
sevier OA license. 1997; McCarthy et al., 2005). However, in the case of HIV infection,
these compounds failed to show protective effects in humans
(Abrams et al., 1989; Van de Wijgert and Shattock, 2007; Cohen,
2008). While the reason of this failure is unclear, it should be
emphasized that GAGs and their mimetics are composed of long
chains bearing anionic residues that bind to viral attachment pro-
teins via multiple electrostatic interactions and consequently this
binding is relatively weak and reversible (non-virucidal) (Neyts
and De Clercq, 1995). In the case of HSV it was found that this kind
of interaction requires the permanent presence of a GAG mimetic
during the virus attachment to cells, and a simple dilution of the
virus-inhibitor complexes was shown to liberate infectious virus
(Vaheri, 1964). These data emphasize the need for structural mod-
iﬁcations of GAG-mimetics in order to confer irreversible binding
to the viral attachment protein and thereby cause permanent inac-
tivation of viral infectivity.
Human RSV targets ciliated cells of the bronchial epithelium
and type 1 pneumocytes in the alveoli (Zhang et al., 2002; Johnson
et al., 2007; Welliver et al., 2007) causing acute bronchiolitis and
pneumonia in infants, the elderly, and immunocompromised indi-
viduals (for review, see Collins and Graham (2008)). Experiments
in cultured cells revealed that an initial step of the RSV infectious
cycle is the binding of the virus attachment protein G (Levine
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1997), mainly to iduronic acid-containing GAGs such as heparan
sulfate or chondroitin sulfate B (Hallak et al., 2000). It is uncertain
whether RSV uses GAGs to infect humans since heparan or chon-
droitin sulfate chains are poorly or not at all expressed at the sur-
face of airway epithelium (Zhang et al., 2005; Monzon et al., 2006).
However another type of GAG chain, i.e., keratan sulfate, is abun-
dantly expressed on the apical surface of ciliated cells of well dif-
ferentiated cultures of bronchial epithelium (Zhang et al., 2002).
This suggests that GAGs or GAG-like receptors may promote RSV
infection of humans, and that compounds that mimic GAG chains
may protect humans from RSV.
The anti-cancer drug candidate muparfostat (formerly known
as PI-88) (Parish et al., 1999) is a mixture of highly sulfated man-
nose-containing di- to hexasaccharides with penta- and tetrasac-
charides as predominant components. In addition to anti-cancer
activities (for review, see Kudchadkar et al., 2008), it also exhibits
anti-HIV (Said et al., 2010), anti-HSV (Nyberg et al., 2004),
anti-dengue and -encephalitic ﬂavivirus (Lee et al., 2006), and
anti-malarial (Adams et al., 2006) activities. In an attempt to im-
prove antiviral activity of muparfostat we paid attention to an
observation that certain polysulfonated compounds such as
PRO2000, composed of chains of aromatic/lipophilic moieties
instead of relatively hydrophilic sugar residues, exhibited virucidal
activity (Cheshenko et al., 2004) and provided some protection of
women against HIV (Cohen, 2009). It has also been reported that
the peptide-based inhibitors of cell entry of HIV (Ingallinella
et al., 2009) or some paramyxoviruses (Porotto et al., 2010) exhib-
ited greatly enhanced antiviral activity when conjugated with
cholesterol. In the present work we conjugated speciﬁc lipophilic
groups to the reducing end of sulfated tetra- and pentasaccharides
and tested whether this modiﬁcation would affect anti-RSV activ-
ity. Our study demonstrated that the cholestanyl-conjugated
tetrasaccharide glycosides exhibited improved anti-RSV potency
including virucidal activity, a feature absent in native sulfated
oligosaccharides.2. Materials and methods
2.1. Cells and viruses
Human laryngeal epidermoid carcinoma (HEp-2) cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 8% fetal calf serum (FCS), 1% L-glutamine, 60 lg/ml of
penicillin, and 100 lg/ml of streptomycin. In most of experiments,
1-day-old cultures of cells at 70% conﬂuence were used. Madin–
Darby canine kidney (MDCK) cells were propagated in Eagle’s
medium supplemented with 5% FCS, 1% tricine and antibiotics.
Laboratory RSV strain A2 (Lewis et al., 1961) was used throughout
the experiments, and its stock was prepared as described by Hallak
et al. (2000) with some modiﬁcations (Lundin et al., 2010). In some
experiments the tissue culture adapted strainA/PR/8/34of inﬂuenza
A virus (IAV) and the Indiana strain of vesicular stomatitis virus
(VSV) were used.2.2. Compounds
Polysulfated tetra- and pentasaccharide glycosides composed of
a(1? 3)/a(1? 2)-linkedmannose residues with speciﬁc lipophilic
groups attached to the reducing end (Table 1) were all prepared and
characterized by 1H NMR, 13C NMR, mass spectrometric, andmicro-
analytical techniques as described previously (Johnstone et al.,
2010). PG545, the cholestanyl b-glycoside of polysulfated maltotet-
raosewas prepared in a similar fashion (Ferro et al., 2008).Muparfo-
stat was prepared as described previously (Cochran et al., 2003). Alltest compounds were solubilized in de-ionized water to a ﬁnal con-
centration of 10 mg/ml and stored at 20 C. All test compounds
maintained good solubility upon their dilution in the cell culture
media.2.3. Viral plaque assays
The plaque number-reduction assay was performed as
described by Lundin et al. (2010). Brieﬂy, test compounds were
serially 5-fold diluted in either DMEM supplemented with 1%
L-glutamine, antibiotics, and 2% heat-inactivated FCS (DMEM-S)
or the same medium without addition of serum (DMEM-NS). Sub-
sequently200 PFU of RSV A2 strain in 50 ll of respective medium
was added to test compounds and incubated for 10 min at room
temperature. HEp-2 cells, seeded in 12-well plates to achieve con-
ﬂuence of 70% after one day of culture, were washed once and
0.5 ml of the virus-compound mixture was added. After co-incuba-
tion of the virus-compound mixture with cells for 2–3 h at 37 C in
a humidiﬁed 5% CO2 atmosphere, the medium was collected and
1.5 ml of 0.75% methylcellulose solution in DMEM-S was added.
To visualize the viral plaques the cells were stained with 1% solu-
tion of crystal violet after 3 days of incubation at 37 C. The effect
of test compounds on VSV infectivity in HEp-2 cells was tested in
the same manner as for RSV using the DMEM-S medium. The effect
of test compounds on IAV was tested in MDCK cells using the viral
cytopathic effect (CPE) reduction method. Brieﬂy, 5-fold dilutions
of test compounds in Eagle’s medium supplemented with 0.25%
bovine serum albumin (BSA), 10 mM HEPES, 0.8 lg/ml of TLCK
trypsin, and antibiotics were mixed with 1000 TCID50 of the virus
and incubated for 10 min at room temperature. MDCK cells, seeded
in 96 well plates, were washed twice with the above described
medium, and the virus-compound mixtures were transferred to
these cells and incubated for 2 h at 37 C. Subsequently the cells
were washed once, and incubated in the same medium for 2 days
at 37 C. For the RSV plaque size-reduction assay, the cells were
inoculated with 100 PFU of the virus for 4 h at 37 C. After wash-
ing of cells, speciﬁc concentrations of test compound in 0.4% meth-
ylcellulose solution were added and incubated with infected cells
for 6 days at 37 C. The cells were stained with 1% solution of crys-
tal violet, and the area of captured images of viral plaques mea-
sured by using IM500 image software (Leica) as described
previously (Ekblad et al., 2010). Statistical analysis was performed
using Student t-test.2.4. Puriﬁcation of radiolabeled virus and virus binding assay
Virus radiolabeling with the expre35S protein labelling mix (Per-
kin Elmer, Upplands Vasby, Sweden) followed by two rounds of
virus puriﬁcation using a 25–55% sucrose linear gradient was per-
formed as described by Techaarpornkul et al. (2001). For the virus
binding assay, the virus was adjusted with Eagle’s medium supple-
mented with 1% BSA to contain 6  105 cpm/ml. Serial 5-fold dilu-
tions of test compounds in Eagle’s medium (0.16–100 lg/ml) were
mixed with the virus (2  104 cpm/well) and incubated for
10 min at 4 C. HEp-2 cells, seeded in 24 well plates to reach a con-
ﬂuence of 90–95% after 2 days of culture, were precooled at 4 C
for 45 min and subsequently washed twice with Eagle’s medium.
The virus-compound mixtures were added to these cells and incu-
bated for 90 min at 4 C under moderate agitation. The cells were
then washed thrice with cold Eagle’s medium, lysed with 200 ll
of 5% SDS solution in PBS, and transferred to scintillation vials for
quantiﬁcation of radioactivity. To study the effect of test com-
pounds on the post attachment step(s), the cells were inoculated
with 200 PFU of non-labeled RSV in DMEM-S for 2 h at 4 C, then
washed twice with cold medium, and incubated with speciﬁc
Table 1
Anti-RSV activity of oligosaccharide glycosides found in a screening assay.
Compound Structure of glycoside Residual infectivity (%)a
Oligosaccharide component Mana(1? 3)/
Mana(1? 2) (No. of residues)
Aglycone component
1 Tetrasaccharide 59.0 ± 9.3
2 Tetrasaccharide 26.6 ± 18.2
3 Pentasaccharide 0.9 ± 1.5c
4 Pentasaccharide 2.3 ± 0.6c
5 Pentasaccharide 0.0 c
6 Pentasaccharide 8.9 ± 2.3
7 Tetrasaccharide 13.6 ± 8.1
8 Tetrasaccharide 20.7 ± 14.2
9 Tetrasaccharide 4.8 ± 3.0
10 Pentasaccharide 3.8 ± 5.4
11 Tetrasaccharide 4.0 ± 5.2
12 Tetrasaccharide 10.3 ± 7.6
13 Pentasaccharide 7.8 ± 6.8
14 Tetrasaccharide 0.0c
PG545 Tetrasaccharideb 0.0c
Muparfostat (PI-88) Mainly penta- and tetrasaccharide None 13.5 ± 5.1
a Percentage of a number of viral plaques found with drug treated virus (100 lg/ml) relative to mock treated controls. Three screening assays were performed.
b Composed of a(1? 4)-linked glucose residues (maltotetraose).
c Statistically signiﬁcant inhibitory effect as related to muparfostat at P value of <0.05 (n = 3).
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37 C. The rest of the procedure was as described in Section 2.3.
2.5. Time-of-addition assay
HEp-2 cells were incubated with test compound (20 lg/ml) in
DMEM-S for periods of 2 h at 37 C which occurred either prior
to, during, or after inoculation of cells with 200 PFU of RSV A2
strain for 2 h at 37 C. Following each treatment and infectionstage, the compound and/or the virus were removed, and the cells
were washed twice and overlaid with a 0.75% methylcellulose
solution in DMEM-S.
2.6. Virus inactivation assay
Approximately 105 PFU of RSV A2 strain and the test compound
at concentrations 1, 10 and 100 lg/ml were added to DMEM-S or
DMEM-NS and mixed in a total volume of 500 ll. The virus-
104 A. Lundin et al. / Antiviral Research 93 (2012) 101–109compoundmixture was incubated for 15 min in a 37 C water bath,
then diluted serially to the non-inhibitory concentration of test
compound, and the residual viral infectivity determined by the vir-
al plaque assay.2.7. Cytotoxicity assay
HEp-2 cells were seeded in 96 well plates to reach a conﬂuence
of 60% after 1 day of culture. The cells were washed with either
DMEM-S or DMEM-NS and 100 ll of the same medium containing
serial 5-fold dilutions of test compound at a concentration range
0.032–500 lg/ml were added in duplicate. The cells and the test
compounds were co-incubated for 72 h at 37 C, and 20 ll of the
CellTiter 96 Aqueous One Solution reagent (Promega, Madison,
USA) was added to each well. Following further incubation for
1–2 h at 37 C, the absorbance at 490 nm against a background of
650 nm was recorded.2.8. Modulation of PG545 antiviral activity by nasal secretions
Human nasal secretions were obtained from three healthy
volunteers. To collect a sample, a cotton swab was inserted into
the posterior area of the nasal cavity and left for 10 s to adsorb
secretions. Swabs were immediately immersed into 1 ml of PBS
in 10 ml tubes, then left at room temperature for 15 min, and
extensively vortexed. Next, the cotton swabs were transferred
to empty, sterile syringes inserted into 12 ml tubes and centri-
fuged for 10 min at 3000g to collect ﬂuid remaining in the swab.
This ﬂuid was pooled with the rest of the sample and stored at
80 C.
Modulation of PG545 activity by nasal secretions was tested as
follows. PG545 at 10-fold increasing concentration (1–1000 lg/ml)
in 25 ll of distilled water was mixed with 200 ll of pooled nasal
secretions and 25 ll of DMEM-NS medium comprising 105 PFU
of the virus. The mixtures were incubated for 15 min at 37 C water
bath, and the residual virus infectivity tested by the plaque assay.2.9. Preparation and analysis of the drug resistant RSV variants
Plaque puriﬁed RSV A2 strain was subjected to 6 or 10 consec-
utive passages in HEp-2 cells in the presence of muparfostat
(50 lg/ml) or to 13 passages in the presence of increasing con-
centrations (1–4.5 lg/ml) of PG545 in DMEM comprising 1%
heat-inactivated FCS. The same virus was also passaged in the ab-
sence of test compound to serve as control material. Any resis-
tance to these compounds was investigated by using the viral
plaque number-reduction assay. Viral variants that survived the
selective pressure of these compounds were plaque puriﬁed twice
and subjected to nucleotide sequencing analysis of genes coding
for the viral G and F proteins as described previously (Lundin
et al., 2010).Table 2
Antiviral activity and cytotoxicity of lipophile-conjugated sulfated oligosaccharide glycosi
Compound Cytotoxicity (CC50; lg/ml) Anti-RSV po
Muparfostat >400 9.9 (>40)b
3 >400 4.6 (>87)
5 NT 5.7
14 113 1.7 (66)
PG545 230 2.2 (105)
a Residual RSV infectivity after incubation for 15 min at 37 C of 105 PFU of the viru
b In parentheses are the values for selectivity index.3. Results
3.1. Anti-RSV activity of lipophile-conjugated sulfated oligosaccharides
Although sulfated oligo- and polysaccharides inhibit RSV infec-
tivity potently, their interaction with viral particles is weak, revers-
ible, and non-virucidal (Neyts and De Clercq, 1995), and complete
virus blockade is difﬁcult to achieve even at relatively high concen-
trations of these compounds (e.g. Hallak et al., 2000, 2007). To
search for GAG mimetics with improved anti-RSV activity polysulf-
ated tetra- and pentasaccharides were chemically modiﬁed by
introduction of different aromatic/lipophilic groups to the reducing
end of the oligosaccharide chain (Table 1). These glycosides were
then screened at 100 lg/ml for anti-RSV activity in cultures of
HEp-2 cells. Because sulfated oligo and polysaccharides including
muparfostat are mixtures of carbohydrate chains of different
molecular weight the test compounds were compared based on
lg/ml rather than on molar values. In contrast to the unmodiﬁed
sulfated oligosaccharides of muparfostat, compounds possessing
dodecyl (3), 12-(4-naphthalen-1-yl-[1,2,3]triazol-1-yl)dodecyl (5)
or cholestanyl (14 and PG545) as the aglycone component demon-
strated complete or near-complete inhibition of RSV infectivity
(Table 1). Moreover, these four glycosides exhibited more favor-
able IC50 values than muparfostat, and showed virucidal activity,
a functional feature absent in muparfostat oligosaccharides
(Table 2). Since PG545 exhibited the most pronounced virucidal
activity, this glycoside was selected for detailed evaluation of
anti-RSV potency. Note that although both PG545 and 14 are com-
posed of a lipophilic cholestanyl group conjugated to a sulfated tet-
rasaccharide, PG545 contains maltotetraose while 14 possesses a
mannose a(1? 3)/(1? 2)-linked tetrasaccharide, as found in
muparfostat, as the oligosaccharide component.
The dose response effects of PG545 on the viability of HEp-2
cells and on infection of these cells by RSV are shown in Fig. 1A.
The anti-RSV activity of the cholestanol-sulfated oligosaccharide
conjugate (PG545) was 5 times greater than that of unmodiﬁed
sulfated oligosaccharide of muparfostat. PG545 completely
blocked RSV infectivity at concentrations ofP20 lg/ml while
unmodiﬁed sulfated oligosaccharides of muparfostat did not dem-
onstrate complete inhibition even at 500 lg/ml. At a concentration
range of 0.16–500 lg/ml muparfostat demonstrated no cytotoxic-
ity while PG545 reduced viability of HEp-2 cells with CC50 value
of 230 lg/ml. Given the presence in PG545 of cholestanol, a sterol
that could interact with many different lipophiles such as serum
apolipoproteins, we tested the cytotoxicity and anti-RSV activity
of PG545 using serum-free media. Under these conditions, the
anti-RSV activity of PG545 was 16 times greater than that of
muparfostat. Note that the absence of serum in the culture med-
ium enhanced both the anti-RSV activity and cytotoxicity of
PG545 by 5-fold (Fig. 1B) as opposed to data obtained in the
presence of serum (Fig. 1A).
We also tested the effect of PG545 on infectivity of IAV or VSV.
The former virus uses sialic acid for initial interaction with cells.
While the cellular receptor for VSV is not known (Coil and Miller,des.
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Fig. 1. Effect of PG545 or muparfostat on RSV infectivity and HEp-2 cell viability.
The test compounds at speciﬁc concentrations in medium comprising 2% heat-
inactivated fetal calf serum (A) or in serum-free medium (B) were either added to
cells and incubated for 3 days at 37 C or incubated with200 plaque-forming units
(PFU) of RSV A2 strain for 10 min prior to and during 2–3 h period of virus infection
of cells. The results are expressed as a percentage of the number of viral PFU found
with drug-treated RSV (infectivity assay) or the number of OD490 units found with
drug-treated cells (cell viability assay) relative to mock-treated controls. Values
shown are means of four determinations from two separate experiments. (C) The
effect of PG545 or muparfostat on vesicular stomatitis virus (VSV) infectivity in
HEp-2 cells was tested in the same manner as for RSV using the medium
supplemented with fetal calf serum. In case of inﬂuenza A virus (IAV), the test
compounds at indicated concentrations in Eagle’s medium supplemented with
0.25% bovine serum albumin (BSA), 10 mM HEPES, 0.8 lg/ml of TLCK trypsin, and
antibiotics were mixed with 1000 TCID50 of the virus and incubated for 10 min at
room temperature. The virus-compound mixtures were transferred to MDCK cells
and incubated for 2 h at 37 C. Subsequently the cells were washed once and
incubated in the same medium for 3 days at 37 C. Two separate experiments were
carried out in quadruplicate wells and the results are expressed as a cumulative
percentage of wells in which cytopathic effect was detected. Calculations were
performed according to Reed–Muench method for computation of 50% endpoints.
A. Lundin et al. / Antiviral Research 93 (2012) 101–109 1052004) this virus is highly sensitive to GAG mimetics (Baba et al.,
1988). PG545 and muparfostat efﬁciently inhibited infectivity of
VSV while showing no effect on IAV infectivity (Fig. 1C).3.2. Mode of anti-RSV action of PG545
To identify which step of the infectious cell cycle of RSV is af-
fected by PG545, the compound was added to HEp-2 cells at differ-
ent time points relative to the virus inoculation. The presence of
compound during the 2 h period of virus attachment to and entry
into the cells resulted in near complete blockade of RSV infectivity
(Fig. 2) indicating that one of the initial steps of RSV infection of
cells is the major target of PG545 activity. In contrast, incubation
of PG545 with cells for a 2 h period occurring just prior to the
RSV inoculation of cells reduced the virus infectivity by 20% sug-
gesting that PG545 could target, although to lesser extent, the non-
infected cells. Likewise, incubation of PG545 with cells for a 2 h
period occurring just after 2 h period of inoculation of cells with
RSV resulted in 60% reduction of RSV infectivity suggesting that
PG545 could affect some steps occurring after virus penetration
into the cells or target the virus particles remaining on the cell sur-
face since the cell entry rate of RSV is known to be relatively slow
(Techaarpornkul et al., 2001).
To clarify which event of the early RSV-cell interaction is
targeted by PG545, the effect of this compound on the virus
attachment to cells was tested. PG545, at a concentration range
of 0.8–100 lg/ml, reduced the binding to cells of puriﬁed and
radiolabeled RSV particles by 50% (Fig. 3A). In contrast muparfo-
stat at 4–100 lg/ml prevented 75% of RSV virions from their
binding to cells. Due to partial reduction of RSV binding to cells
by PG545, we sought to investigate whether this compound could
interfere with the events of RSV cycle occurring after the virus
attachment to cells. To this end, the virus was adsorbed to cells
for 2 h at 4 C prior to the addition of PG545 in warm medium
to trigger the entry of preadsorbed virus into the cells. Under
these conditions PG545, and to lesser degree muparfostat,PF
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Fig. 2. Anti-RSV activity of PG545 added to cells at different time-points relative to
RSV inoculation. One day old cultures of HEp-2 cells, seeded in 12 well plates, were
washed twice with 1 ml of DMEM-S medium, and PG545 (20 lg/ml) in the same
medium was added and incubated for 2 h period which occurred either prior to,
during, or after inoculation of the cells with 200 plaque-forming units (PFU) of
RSV A2 strain for 2 h at 37 C. The cells were washed twice with 1 ml of DMEM-S
medium after each period of their incubation with the drug and/or the virus and
overlaid with 1.5 ml of 0.75% methylcellulose solution. After 3 days of incubation at
37 C, the cells were stained with 1% solution of crystal violet and the viral plaques
counted. Three separate experiments were carried out in duplicate, and the results
are expressed as a percentage of the number of viral PFU found with compound
treated virus and/or cells relative to mock-treated controls. Statistically signiﬁcant
differences as related to controls at P values of <0.005 (⁄⁄⁄) or <0.01 (⁄⁄).
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Fig. 3. Effect of PG545 on the binding of RSV to cells and on infection of cells by
preadsorbed virus. The test compounds at indicated concentrations were mixed
with puriﬁed [35S]-labeled RSV virions (20,000 cpm) and incubated at 4 C for
10 min prior to and during 90 min period of virus attachment to HEp-2 cells under
moderate agitation. The cells were washed 3 times with cold Eagle’s medium, lysed
with 5% SDS, and transferred to scintillation vials for quantiﬁcation of radioactivity
(A). The cells were inoculated with 200 plaque-forming units (PFU) of RSV A2
strain in DMEM-S medium for 2 h at 4 C, then washed with cold medium, and
incubated with speciﬁc concentrations of test compounds for 2 h at 37 C (B). Two
separate experiments were carried out in duplicate, and the results are expressed as
a percentage of attached viral cpm (A) or a percentage of a number of PFU (B) found
with compound-treated virions relative to mock-treated controls.
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indicating that this compound could either displace the cell-at-
tached virus or block the virus entry into the cells. Altogether,
these data suggest that PG545 acts, at least in part, through inhi-
bition of RSV attachment to and entry into the cells. Furthermore,
presence of PG545 in culture medium throughout the develop-
ment of viral plaques reduced their size by 42% (P < 0.005). In
particular, the mean area of viral plaques (n = 28) developed
6 days after inoculation in mock-treated cells and in the presence
of PG545 (4 lg/ml) was 0.31 ± 0.13 and 0.18 ± 0.06 mm2, respec-
tively (data not shown).
To identify which component of RSV particles is targeted by
PG545, we attempted to select viral variants resistant to this com-
pound. For comparative purposes, we also attempted to select vir-
al variants resistant to muparfostat. To this end, plaque puriﬁed
RSV A2 strain was subjected to 10 passages in HEp-2 cells in the
presence of muparfostat (50 lg/ml) or to 13 passages in the pres-
ence of increasing concentrations (1–4.5 lg/ml) of PG545. The
virus was also mock-passaged in the absence of the test com-
pounds to serve as controls. However, the PG545 resistance of
RSV generated in this way was not apparent. In particular, thisvirus could resist a maximum 4.5 lg/ml of the compound. Fur-
thermore, it required 2–3 days longer to produce complete CPE
in the presence of PG545 than in its absence, and its resistance
to PG545 assessed by the dose-dependent viral plaque assay,
was only 3- to 4-fold higher than that of original virus (Table
4). Nonetheless, sequencing of the PG545 resistant virus and its
comparison with the original and mock-passaged RSV revealed
presence of the F168S and the P180S amino acid substitutions in
the G protein in all three virus variants examined, and the V516I
amino acid alteration in the F protein in variant A (Table 4). Be-
cause alteration in the F protein was not found in all variants
tested and the resistance of this variant was not substantially
different from variants lacking this alteration, this mutation in
contrast to alterations in the G protein is likely to be irrelevant
for the resistant phenotype.
RSV variants generated by selective pressure from muparfostat
in 10 passages in HEp-2 cells were readily selected and appeared to
be7–9 times more resistant to this compound than original virus.
All three plaque variants of resistant virus comprised the N191T
amino acid change in the viral attachment protein G (Table 4). In
addition to this mutation, variant A also contained the D126E ami-
no acid substitution and the t642c (silent) nucleotide alteration in
the G component. Because the drug resistance of variant A was
similar to variants B and C, the N191T amino acid change in the
G protein seemed to confer RSV resistance to muparfostat. In rep-
etition of this experiment, the RSV was subjected to 6 passages in
HEp-2 cells in the presence of muparfostat and two viral variants
were plaque puriﬁed and analyzed. Both variants were resistant
to muparfostat and in contrast to initial or mock-passaged virus
comprised the N191T amino acid substitution in the G protein
(data not shown). One of these plaques also contained the K197T
alteration in the G protein. These data conﬁrm that the N191T
alteration in the G protein is responsible for resistance of RSV to
muparfostat.
3.3. Virucidal activity of PG545
Data presented in Table 2 indicate that, unlike the sulfated oli-
gosaccharides of muparfostat, inhibition of RSV infectivity by
PG545 is associated with virucidal activity of this compound. The
term ‘‘virucidal activity’’ is usually applied to agents that are capa-
ble of neutralizing, inactivating or destroying a virus permanently.
We tested the virucidal potency of PG545 in a dose dependent
manner. To this end, PG545 at the indicated concentrations and
105 PFU of RSV A2 strain were mixed in medium comprising 2%
heat-inactivated FCS or in serum-free medium and incubated for
15 min at 37 C. Subsequently, the virus-compound mixture was
serially diluted and the residual virus infectivity determined at
the non-inhibitory concentrations of PG545. In contrast to mupar-
fostat, PG545 exhibited virucidal activity (Table 3). This activity of
PG545 was most pronounced in the serum-free medium where
10 lg/ml of compound completely inactivated infectivity of
105 PFU of RSV. These results indicate that some components of
FCS decreased anti-RSV activity of PG545.
Since RSV infecting cells of human airway epithelium repre-
sents an obvious target for PG545, we sought to determine
whether nasal secretions would modify anti-RSV activity of this
compound. To this end pooled nasal secretions, collected and pre-
pared as described in Section 2.8, were mixed with different con-
centrations of PG545 and 105 PFU of RSV, and incubated for
15 min at 37 C. Comparative analysis of infectious titers of
survived virus (Table 5) revealed that human nasal secretions
decreased RSV infectivity by 4.4-fold. Moreover, human nasal
secretions reduced anti-RSV activity of PG545. This effect was
clearly seen at a concentration of 10 lg/ml of PG545 that com-
pletely inhibited (P99.98%) RSV infectivity in the absence of nasal
Table 3
The virus-inactivating activities of muparfostat and PG545.a
Compound concentration (lg/ml) Muparfostat PG545
Serum No serum Serum No Serum
100 122.4 ± 8.5 b 151.1 ± 10.7 6.1 ± 5.4 0
10 97.9 ± 3.0 113.7 ± 21.7 62.8 ± 2.4 0
1 101.5 ± 3.6 116.7 ± 16.8 88.8 ± 2.8 35.5 ± 26.5
a Test compounds at speciﬁc concentrations in the medium supplemented with 2% fetal calf serum or in the serum-free medium were mixed with 105 plaque-forming
units of RSV A2 strain and incubated for 15 min at 37 C water bath. The mixture was then serially diluted in the same medium and the residual virus infectivity determined.
b Mean percentage of residual virus infectivity as related to mock-treated virus found in two separate experiments.
Table 4
Alterations detected in the PG545 or muparfostat resistant variants of RSV.
Virus variant Alterationa Sensitivity IC50 (lg/ml)
Nucleotide Amino acid (protein)
Muparfostat Initialb None None 11
A t486 g D162E (G) >100 (>9)c
a572c N191T (G)
t642c Silent
B a572c N191T (G) 100 (9)
C a572c N191T (G) 80 (7)
PG545 Initial None None 1.4
A t503c F168S (G) 6.2 (4)
c538t P180S (G)
g1546a V516I (F)
B t503c F168S (G) 4.8 (3)
c538t P180S (G)
C t503c F168S (G) 4.6 (3)
c538t P180S (G)
a Detected by comparison of the nucleotide sequences of RSV subjected to serial passages in the presence of PG545 or muparfostat with these of initial virus or mock-
passaged virus in the absence of test compounds.
b Plaque puriﬁed RSV A2 strain that served as starting material for the virus passages.
c Fold resistance to test compounds as related to initial virus is shown in parentheses.
Table 5
Modulation of anti-RSV activity of PG545 by human nasal secretionsa.
PG545 (lg/ml) Residual RSV infectivity (PFU/ml) with
Nasal secretions (+) Nasal secretions ()
0 2.5  104 1.1  105
1 3.1  104 4.0  104
10 9.9  103 <2  101
100 <2  101 <2  101
1000 <2  101 NT
a PG545 at indicated concentration in 25 ll of distilled water was mixed with
200 ll of pooled nasal secretions and 25 ll of DMEM-NS medium comprising
105 PFU of the virus. The mixtures were incubated for 15 min at 37 C water bath,
and the residual virus infectivity tested by the plaque assay. Results shown are
means of two determinations from two separate experiments.
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this body ﬂuid. The inhibitory effect of nasal secretions on anti-
RSV activity of PG545 was not detected at concentra-
tionsP100 lg/ml. The IC50 values for PG545, calculated based on
data shown in Table 5, were 7 and 0.6 lg/ml when tested in the
presence and absence of nasal secretions, respectively. This sug-
gests that under experimental conditions described above 11
times more of PG545 would be required to overcome inhibitory ef-
fect of nasal secretions.4. Discussion
We found that the anti-RSV activity of polysulfated oligosaccha-
rides was greatly improved following their conjugation with cho-
lestanol, a derivative of cholesterol, a molecule that is a frequentcomponent of antimicrobial lipids of airway secretions (Do et al.,
2008). In addition to improved IC50 values, this modiﬁcation en-
dowed oligosaccharides with virucidal activity, a feature that
seems to be of importance in possible clinical application of GAG
mimetics. This possibility is supported by observation that poly-
sulfonated compound PRO2000, a linear polymer of relatively
hydrophobic naphthalene 2-sulfonate, exhibited virucidal activity
when tested with HSV (Cheshenko et al., 2004) and provided some
protection of women against HIV (Cohen, 2009). In contrast,
sulfated oligo- and polysaccharides such as cellulose sulfate or car-
rageenan that exhibited little or no virucidal activity (Carlucci
et al., 1999; Cheshenko et al., 2004) failed in large clinical trials
to protect women against HIV infection (Van de Wijgert and Shat-
tock, 2007; Cohen, 2008) in spite of their potent antiviral activity in
cultured cells.
The most active glycoside PG545, an anticancer drug candidate
currently in Phase I clinical trials (Dredge et al., 2011), composed of
cholestanol conjugated to polysulfated maltotetraose, inhibited
RSV infection of HEp-2 cells with an IC50 value of 2.2 lg/ml while
the 50% cytotoxic dose of this compoundwas 230 lg/ml. The struc-
tural design of PG545 is to some extent similar to that of NMSO3, a
glycoside known for its potent anti-RSV activity (Kimura et al.,
2000). This glycoside is composed of polysulfated mono-sialic acid
conjugated to two alkyl chains of C22H45 as the lipophilic aglycone
component, and its IC50 value for RSV Long strain ranged from 0.3
(Kimura et al., 2000) to 6 lg/ml (Wyde et al., 2004) while 50% cyto-
toxic concentration ranged from 750 lg/ml (Wyde et al., 2004) to
>1 mg/ml (Kimura et al., 2000). Modiﬁcation of sulfated oligosac-
charides with a relatively short alkyl chain (dodecyl) was em-
ployed in glycoside 3 (Table 1) which exhibited a favorable IC50
value and no cytotoxicity (Table 2), however, due to modest
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pronounced virucidal activity was observed in PG545 and it is dif-
ﬁcult to compare it with NMSO3 since no data on the virucidal
activity of this compound was reported. We found that the viru-
cidal activity of PG545 was decreased in the presence of FCS in cul-
ture medium, and this observation is not surprising since sterols
can interact with several serum proteins including apolipoproteins.
More importantly, because PG545 would need to target RSV
infecting cells of the airway, we tested whether the antiviral activ-
ity of this compound is modulated in the presence of human nasal
secretions. We found that pooled preparations of nasal secretions
can inhibit RSV infectivity. The anti-RSV activity of nasal secretions
could be exerted by some components of this body ﬂuid such as
surfactant proteins (Ghildyal et al., 1999), antimicrobial peptides
(Laube et al., 2006; Kota et al., 2008), mucins (Rubin, 2002), or cho-
lesteryl esters (Do et al., 2008). Moreover, we found that human
nasal secretions reduced anti-RSV activity of PG545, however, this
inhibitory effect could be overcome by using higher concentrations
of PG545. Further studies employing a model of RSV infection of
well-differentiated cultures of human airway epithelium (Zhang
et al., 2002) are needed to assess modulation of anti-RSV activity
of PG545 by airway mucus.
The capability of PG545 and related glycosides to interact with
serum proteins did not seem to limit their in vivo application. In
fact, the presence of the lipophilic moiety in PG545 and related gly-
cosides helped to overcome two major disadvantages associated
with in vivo usage of sulfated oligo- and polysaccharides, i.e., it
greatly attenuated their anticoagulant activity and prolonged the
half life of these compounds in the body (Johnstone et al., 2010;
Dredge et al., 2011). Due to the presence of sulfate groups in
PG545 and related glycosides, these compounds can inhibit the
interaction between a plethora of different proteins and sulfated
GAGs. Thus, interference of PG545 with the activity of vascular
endothelial and ﬁbroblast growth factors inhibited angiogenesis,
a key process in tumor development, while binding to heparanase,
an enzyme abundantly expressed on neoplastic cells, limited their
metastasis (Dredge et al., 2010, 2011; Johnstone et al., 2010). Both
these functional features confer potent anti-cancer activities on
PG545 (Dredge et al., 2011).
How exactly does the presence of a lipophilic moiety alter the
interaction of sulfated oligosaccharides with RSV? We found that
PG545 preferably interacted with RSV and to lesser extent with
cells, and blocked initial events of RSV invasion of cells. Sulfated
oligo- and polysaccharides (Krusat and Streckert, 1997; Kwilas
et al., 2009) including muparfostat (this report) target mainly the
RSV attachment protein G. Indeed, analysis of the viral variants
resistant to muparfostat revealed a G protein mutation, N191T,
occurring in the heparin-binding domain (Feldman et al., 1999)
responsible for interaction of this protein with GAGs. Interestingly,
in HSV muparfostat targeted proteins that, like RSV G protein, con-
tain the mucin-like region, and the resistant variants of HSV-1 ex-
pressed attachment protein gC with the entire mucin-like segment
deleted (Ekblad et al., 2007) while HSV-2 produced no envelope
glycoprotein gG (Adamiak et al., 2007). In contrast to muparfostat,
RSV variants resistant to PG545 exhibited only a weak resistance to
this drug. Nonetheless, these weakly resistant variants comprised
two amino acid substitutions F168S and P180S in the central re-
gion of the G protein that includes the cysteine noose. Thus, anal-
ysis of RSV variants resistant to muparfostat and PG545 indicates
that both these compounds target the G protein. However, in com-
parison with muparfostat, PG545 reduced the virus attachment to
cells less extensively while demonstrating a more pronounced
inhibitory effect on infection of cells by virus that was adsorbed
to cells at 4 C prior to the addition of PG545. Collectively, poor
resistance of RSV to PG545 and moderate reduction of the virus
binding to cells by this compound suggest that in addition to theG protein PG545 may target other components of the viral enve-
lope. Indeed, an expected afﬁnity of cholestanol component of
PG545 for lipid membranes suggests that this compound could
be inserted into the viral lipid envelope thus creating a coat of arti-
ﬁcial sulfo-glycolipids/sterols, a structure that could prevent fusion
of viral and cellular membranes and thereby neutralize the virus.
Lack of PG545 activity against inﬂuenza A virus, a pathogen that
does not require GAGs for initial binding to cells, suggests that
the sulfated oligosaccharide component of PG545 can be responsi-
ble for speciﬁc afﬁnity of this compound for the GAG-binding
viruses, an event followed by hydrophobic interaction of cholesta-
nol with viral lipids. Thus, it is likely that PG545 may target more
than one viral component to exhibit anti-RSV activity. Mutations
detected by us in the G protein were not found in the published se-
quences of clinical isolates of RSV. It is noteworthy that another
cholestanol- tetrasaccharide conjugate 14 failed to generate resis-
tance in HSV-2 (Ekblad et al., 2010). Kimura et al. (2004) generated
NMSO3 variants of RSV Long strain which, following 15 and 33
passages in HEp-2 cells, achieved 4.8- and 9.3-fold resistance to
this drug. The NMSO3 resistant phenotype was due to numerous
mutations in the G protein, however a single amino acid substitu-
tion in the F protein was also detected (Kimura et al., 2004). One of
the mutations detected by these authors in the G protein after 33
NMSO3 passages (i.e., F168S) was also detected by us in the
PG545 resistant RSV.
In conclusion, PG545 is a novel inhibitor of RSV that exhibits
virucidal activity, and the development of RSV resistance to this
compound is slow. Given the fact that PG545 and related glyco-
sides also exhibited potent virucidal activities against HSV (Ekblad
et al., 2010) and HIV (Said et al., 2010), the cholestanyl-conjugated
oligosaccharides are promising lead compounds for treatment and/
or prevention of infections caused by viruses that use GAGs as ini-
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